Prenuvo Launches FDA-Cleared AI-Powered Whole Body MRI Screening Products

 

Prenuvo has achieved a significant milestone with FDA clearance for its AI-powered Prenuvo Body Composition report, marking a pivotal moment in the company’s evolution. Expanding on this achievement, Prenuvo introduces three major advancements:

1. AI-Powered Whole-Body Composition Analysis: This non-invasive platform provides precise, actionable data on visceral fat, subcutaneous fat, liver fat, muscle volumes, and vital abdominal organ volumes. It empowers patients with personalized reports to make informed lifestyle choices and proactive health decisions.
2. Innovative Brain Health Scan: Offering critical insights into brain function, cognitive health, and early signs of neurodegenerative conditions.
3. Comprehensive Blood Biomarker Assessment: Utilizing a custom panel of tests to deepen insights into metabolic, cardiovascular, hormonal, and immune health, synergizing effectively with imaging data.

These new capabilities are launching immediately under the bundled offering named Prenuvo Enhanced, initially available in Silicon Valley, Los Angeles, and New York, with wider availability in the spring. For those interested, sign up for waitlist notifications at Prenuvo Enhanced Screening.

“Last year showed a clear shift towards proactive health management,” noted Sundeep Peechu, Managing Partner at Felicis. “Prenuvo’s integrated model and advanced screenings position them uniquely to lead this transformation in preventative healthcare.”

In 2024, Prenuvo secured $120M in Series B funding, surpassing 110,000 members and identifying over 1.4 million personalized health insights. This milestone underscores the company’s commitment to early detection and proactive health.

According to Andrew Lacy, CEO of Prenuvo Inc., “Prenuvo is spearheading a movement to democratize proactive healthcare. Our approach to early detection empowers individuals to manage their health proactively, leveraging cutting-edge technology to prevent disease and enhance longevity.”

This initiative isn’t just about healthcare; it’s about redefining our approach to health, enabling people to live longer and healthier lives through innovation and expertise.

______________

RadParts, a TTG Imaging Solutions Company, is the world’s largest independent distributor of OEM replacement parts. We specialize in low-cost parts for repairing linear accelerators and radiation equipment. Our mission is to provide high-quality, user-friendly, low-cost components and support for linear accelerators and radiation equipment. Contact RadParts at 877-704-3838 to learn more.

Written by the Digital Marketing Team at Creative Programs & Systems: https://www.cpsmi.com/.

Linear Particle Accelerators Market: A Thriving Industry with Expanding Horizons

 

The global Linear Particle Accelerators (Linacs) Market is set to achieve significant growth, projected to reach a value of $4.8 billion by 2033, up from $2.7 billion in 2023. This represents a steady compound annual growth rate (CAGR) of 5.7% from 2024 to 2033. Linacs, critical in advancing medical, industrial, and scientific applications, are becoming indispensable in modern technology. With North America leading the market, accounting for 45.1% of the share in 2023, and Asia-Pacific emerging as a growth hub, this sector is on a path of robust development.

Advancing Healthcare Applications

Linear accelerators play a vital role in healthcare, particularly in radiation therapy for cancer treatment. By delivering precise doses of radiation directly to tumors while sparing surrounding healthy tissue, Linacs have revolutionized oncology care. Today, 60% of cancer treatments globally involve radiation therapy, underscoring the essential role of Linacs in modern medicine. Hospitals, the leading end-users, account for 61% of the market share, integrating Linacs for innovative treatments and imaging techniques like PET/CT scans.

Industrial and Scientific Growth

Beyond healthcare, Linacs are making strides in industrial and scientific applications. They are used for non-destructive testing, ensuring quality in aerospace, automotive, and construction sectors. In scientific research, Linacs enable groundbreaking experiments in particle physics and materials science, pushing the boundaries of innovation. High-energy accelerators, which constituted 42% of the market in 2023, are instrumental in these advancements, achieving near-light-speed particle acceleration.

Technological Innovations: AI and Beyond

The integration of artificial intelligence (AI) is transforming the Linacs market. AI-driven solutions optimize performance, improve beam stability, and enable predictive maintenance, reducing downtime and operational costs. Research is advancing toward autonomous operation, where Linacs self-adjust in real-time for maximum efficiency. Other technological trends include miniaturization, making Linacs more portable and versatile, and the development of energy recovery systems, which enhance sustainability.

Emerging Trends and Opportunities

Innovation continues to redefine the Linacs market. Plasma-based accelerators, for example, leverage compact designs to reduce the size of traditional accelerators dramatically. Programs like the Linac for Image-Guided Hadron Therapy (LIGHT) aim to make proton therapy more accessible, broadening medical treatment options. Similarly, energy recovery Linacs (ERLs) are improving efficiency by recycling energy, reducing operational costs and environmental impact.

Challenges and Market Dynamics

Despite its rapid growth, the Linacs market faces challenges, primarily high operational costs. Energy-intensive systems and significant upfront investments remain barriers, particularly for smaller institutions. However, advancements in superconducting materials and energy-efficient designs are addressing these concerns, paving the way for broader adoption across industries.

The Future of the Linacs Market

With its diverse applications and ongoing technological advancements, the Linear Particle Accelerators Market is poised for sustained growth. Innovations in healthcare, industry, and research are solidifying Linacs’ position as a cornerstone technology. As the market expands into new regions like Asia-Pacific, fueled by investments in healthcare and industrial infrastructure, Linacs will continue to shape the future of medical treatment, scientific discovery, and industrial innovation.

By embracing these trends and addressing existing challenges, the Linacs market is set to achieve its $4.8 billion potential by 2033, cementing its role in driving progress across multiple sectors.

To read the original article, visit: https://media.market.us/linear-particle-accelerators-market-news/

For affordable parts to repair linear accelerators, radiation equipment, and more, contact RadParts.

RadParts, a TTG Imaging Solutions Company, is the world’s largest independent distributor of OEM replacement parts. We specialize in low-cost parts for repairing linear accelerators and radiation equipment. Our mission is to provide high-quality, user-friendly, low-cost components and support for linear accelerators and radiation equipment. Contact RadParts at 877-704-3838 to learn more.

 

Written by the Digital Marketing Team at Creative Programs & Systems: https://www.cpsmi.com/.

Prevention and Screening: Major Contributors to Saving Lives in Five Key Cancer Types

 

A recent study led by the National Institutes of Health (NIH) and published in JAMA Oncology highlights the significant impact of prevention and screening in reducing mortality from five major cancer types over the last 45 years. The research focused on breast, cervical, colorectal, lung, and prostate cancers, which collectively represent nearly half of all cancer diagnoses and deaths. This study underscores that while treatment advances are often viewed as the primary contributors to mortality reduction, prevention and screening have played a more substantial role in saving lives.

Co-lead investigator Katrina A. B. Goddard, Ph.D., from the NCI's Division of Cancer Control and Population Sciences, emphasized that 80% of the deaths averted from these cancers since 1975 can be attributed to advances in prevention and screening rather than treatment. Particularly notable is the impact of smoking cessation, which alone accounted for 3.45 million lives saved from lung cancer. The study further found that prevention and screening were the predominant factors in reducing deaths from cervical, colorectal, lung, and prostate cancers, while treatment advances led in breast cancer mortality reduction.

The study utilized statistical models to analyze cancer mortality data between 1975 and 2020, revealing that 5.94 million deaths were prevented due to interventions in these five cancers, with prevention and screening accounting for 4.75 million of these. The breakdown by cancer type showed varying contributions of screening and treatment. For example, in lung cancer, tobacco control was overwhelmingly effective, accounting for 98% of the averted deaths. Conversely, in breast cancer, treatment was the major contributor, although mammography screening also played a significant role.

These findings underscore the necessity of a multifaceted approach to cancer reduction, combining effective prevention, screening, and treatment strategies. W. Kimryn Rathmell, M.D., Ph.D., director of NCI, stated that understanding which strategies are most effective helps guide future efforts to reduce cancer mortality further. The study also points to recent advancements like HPV vaccination and lung cancer screening, which could potentially enhance these effects even though they were not widely used during the study period.

However, the researchers acknowledge that the study's focus on these five cancers, which represent less than half of all cancer deaths, means the findings might not apply to cancers without effective prevention, screening, or treatment options. Dr. Philip E. Castle, another co-lead investigator, emphasized the importance of optimizing and expanding access to proven interventions, particularly for underserved populations, and developing new strategies for other lethal cancers such as pancreatic and ovarian cancer.

The authors also noted limitations, including the study's reliance on population averages and its exclusion of potential screening harms like false positives and overdiagnosis. These findings present a complex picture of cancer prevention and treatment, highlighting the critical role of integrated strategies in ongoing efforts to reduce cancer mortality across various populations.

 

______________

RadParts, a TTG Imaging Solutions Company, is the world’s largest independent distributor of OEM replacement parts. We specialize in low-cost parts for repairing linear accelerators and radiation equipment. Our mission is to provide high-quality, user-friendly, low-cost components and support for linear accelerators and radiation equipment. Contact RadParts at 877-704-3838 to learn more.

 

Written by the Digital Marketing Team at Creative Programs & Systems: https://www.cpsmi.com/.

 

Can AI Improve Early Detection of Breast Cancer in MRI Studies?

 

Recent research indicates that using artificial intelligence (AI) to reevaluate breast MRIs deemed high-risk could markedly enhance early breast cancer detection. A retrospective study published in Academic Radiology examined the effectiveness of a convolutional neural network trained on breast MRI data to predict breast cancer development within a year following initially negative MRI results. The study involved 3,029 MRI scans from 910 patients (average age 52), including 115 cases where breast cancer was later diagnosed on MRI. Initially, all patients received a BI-RADS assessment of less than 3.

The study found that the AI model predicted breast cancer within one year with a 72 percent accuracy as measured by the area under the receiver operating characteristic curve (AUC). Of the initial MRI scans, 83 out of 115 cases showed visual correlations with biopsy-proven breast cancer, with the majority of these correlations measuring less than 0.5 cm.

The researchers emphasized that using the AI model to reassess MRIs identified as high-risk could improve early breast cancer detection rates by up to 30 percent. "It's crucial to recognize that the reported 30% sensitivity refers to cancers that would likely have remained undetected until the subsequent exam. These are additional detections, supplementing those already identified with high sensitivity by radiologists," explained lead study author Dr. Lukas Hirsch of the City College of New York.

The study also highlighted that with the AI model’s reassessment, the positive predictive value (PPV) could reach 6 percent for high-risk MRI scans. If radiologists were to recall only half of these cases, they would achieve the PPV standard for tissue diagnosis and detect at least an additional 15% of tumors, representing a clinically significant improvement.

Furthermore, the AI model successfully pinpointed the future location of breast cancer in 57 percent of the cases, with a 71 percent accuracy rate in the 35 true positive cases.

Despite the promising results, the study’s authors acknowledged several limitations, including the single-center, retrospective nature of the study, the assessment limited to sagittal scans, and the small number of cancers detected through screening.

_________

RadParts, a TTG Imaging Solutions Company, is the world’s largest independent distributor of OEM replacement parts. We specialize in low-cost parts for repairing linear accelerators and radiation equipment. Our mission is to provide high-quality, user-friendly, low-cost components and support for linear accelerators and radiation equipment. Contact RadParts at 877-704-3838 to learn more.

 

Written by the Digital Marketing Team at Creative Programs & Systems: https://www.cpsmi.com/.